Status:

TERMINATED

A Study of Renal Denervation in Patients With Treatment Resistant Hypertension

Lead Sponsor:

Dr. Harindra Wijeysundera

Collaborating Sponsors:

Medtronic

Mars Excellence in Clinical Innovation and Technology Evaluation

Conditions:

Treatment-Resistant Hypertension

Eligibility:

All Genders

18+ years

Phase:

NA

Brief Summary

The purpose of this study is to evaluate the clinical and economic impact of implementation of renal denervation with the Symplicity™ Catheter System for treatment-resistant hypertension in Ontario, C...

Detailed Description

This is a pragmatic randomized trial of renal nerve denervation for treatment resistant hypertension. This is part of a ministry sponsored MaRS-EXCITE program, to conduct early market health technolog...

Eligibility Criteria

Inclusion

  • Ontario residents
  • Aged 18 and over
  • Diagnosis of treatment-resistant hypertension after assessment and optimization by a hypertension specialist following recommended evaluation and diagnosis as outlined by the American Heart Association
  • Office systolic blood pressure ≥ 160 mmHg (≥ 150 mmHg for patients with type II diabetes mellitus) prior to optimization by a hypertension specialist
  • Baseline average systolic 24 hour ambulatory blood pressure of ≥ 135 mmHg after optimization and prior to randomization
  • Prescribed 3 or more antihypertensive medications of different classes, both prior to optimization and at randomization, one of which must be a diuretic (a medication can be counted more than once if it acts on different receptors)
  • Suitable renal artery anatomy based on CT/MRI/renal angiography imaging: both renal arteries \> 20 mm in length and \> 4 mm in diameter without significant fibromuscular disease or renal artery stenosis (\>50%)

Exclusion

  • Secondary causes of hypertension:
  • Primary aldosteronism (secondary to adrenal adenoma)
  • Chronic kidney disease: creatinine clearance or eGFR \< 45 ml/min/1.73m² (measured on 24 hour urine preferably or MDRD)
  • Pheochromocytoma
  • Cushing's syndrome
  • Aortic coarctation (differential in brachial or femoral pulses, systolic bruit)
  • Type 1 diabetes mellitus
  • Pregnancy

Key Trial Info

Start Date :

October 1 2013

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

October 1 2014

Estimated Enrollment :

8 Patients enrolled

Trial Details

Trial ID

NCT01895140

Start Date

October 1 2013

End Date

October 1 2014

Last Update

October 13 2014

Active Locations (2)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (2 locations)

1

Sunnybrook Research Institute

Toronto, Ontario, Canada, M4N 3M5

2

St. Michael's Hospital

Toronto, Ontario, Canada, M5B 1W8